AxoGen, Inc. (AXGN)
Market Cap | 394.11M |
Revenue (ttm) | 133.96M |
Net Income (ttm) | -28.82M |
Shares Out | 42.29M |
EPS (ttm) | -0.67 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 234,563 |
Open | 9.92 |
Previous Close | 9.90 |
Day's Range | 9.03 - 10.02 |
52-Week Range | 6.87 - 13.66 |
Beta | 0.52 |
Analysts | Buy |
Price Target | 17.51 (+86.67%) |
Earnings Date | Mar 14, 2023 |
About AXGN
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM... [Read more]
Financial Performance
In 2021, Axogen's revenue was $127.36 million, an increase of 13.41% compared to the previous year's $112.30 million. Losses were -$26.99 million, 13.4% more than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for AXGN stock is "Buy." The 12-month stock price forecast is $17.51, which is an increase of 86.67% from the latest price.
News

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022
ALACHUA, Fla. and TAMPA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

Axogen to Participate at J.P. Morgan 41st Annual Healthcare Conference
ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

Axogen Patient to Ride the 2023 Donate Life Rose Parade® Float Supporting awareness of organ and tissue donation
ALACHUA, Fla. and TAMPA, Fla., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

Here's Why "Trend" Investors Would Love Betting on AxoGen (AXGN)
If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price St...

AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of 93.33% and 2.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Axogen, Inc Reports 2022 Third Quarter Financial Results
ALACHUA, Fla. and TAMPA, Fla., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

Axogen to Participate at Upcoming Investor Conferences
ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

Axogen, Inc. announces the appointment of Adrian Tyndall, M.D. MPH, FACEP to its Board of Directors and the retirement of founding Director Mark Gold, M.D.
Dr. Tyndall is currently the Executive Vice President for Health Affairs and Dean of Morehouse School of Medicine. Dr. Tyndall is currently the Executive Vice President for Health Affairs and Dean of ...

AxoGen (AXGN) Upgraded to Buy: Here's What You Should Know
AxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Axogen, Inc. to report third quarter 2022 financial results and host conference call on November 8, 2022
ALACHUA and TAMPA, Fla., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today a...

AxoGen (AXGN) Soars 8.6%: Is Further Upside Left in the Stock?
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t...

Axogen to Participate in the 77th Annual Meeting of the American Society for Surgery of the Hand
Industry leading nerve repair surgeons will discuss data-driven best practices during symposium session Industry leading nerve repair surgeons will discuss data-driven best practices during symposium ...

Wall Street Analysts Think AxoGen (AXGN) Could Surge 89%: Read This Before Placing a Bet
The consensus price target hints at an 89.4% upside potential for AxoGen (AXGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate ...

AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of 60% and 5.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Axogen, Inc Reports 2022 Second Quarter Financial Results
ALACHUA, Fla. and TAMPA, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...

Axogen, Inc. to present at Canaccord Genuity's 42nd Annual Growth Conference
ALACHUA. Fla. and TAMPA, Fla, July 29, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, to...

Axogen, Inc. Announces Organizational Updates, Preliminary Second Quarter Revenue and Reaffirms Full-Year 2022 Financial Guidance
Organizational updates are part of plan to bring additional focus on leveraging clinical data to accelerate market development and the pace of innovation

Axogen, Inc. Appoints William Burke to Board of Directors
Burke brings 25+ years of global financial leadership experience to the Axogen, Inc. Board of Directors Burke brings 25+ years of global financial leadership experience to the Axogen, Inc. Board of Di...

Axogen Aces Phase 3 Study For Avance Nerve Graft
Axogen Inc (NASDAQ: AXGN) announced topline results from its RECON Clinical Study comparing Avance Nerve Graft to conduits in digital nerve injuries. Avance Nerve Graft is a biologically active off-t...

AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of -17.65% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Axogen, Inc Reports 2022 First Quarter Financial Results
ALACHUA, Fla. and TAMPA, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, to...

Axogen, Inc. Announces Positive Topline Results from Phase 3 RECON(SM) Study for Avance® Nerve Graft
RECON achieved its Primary Endpoint, a critical milestone toward transitioning Avance Nerve Graft to a licensed biologic and further supporting the expanded adoption of Avance RECON achieved its Prima...

Axogen, Inc. to Report First Quarter 2022 Financial Results and Host Conference Call on May 4, 2022
ALACHUA, Fla. and TAMPA, Fla., April 13, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, ...

Axogen, Inc. publishes inaugural ESG Report
ALACHUA, Fla. and TAMPA, Fla., March 17, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, ...

AxoGen (AXGN) Reports Q4 Loss, Tops Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of 38.46% and 0.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?